Kayyem Jon Faiz 4
4 · Inhibrx Biosciences, Inc. · Filed Jun 4, 2024
Insider Transaction Report
Form 4
Kayyem Jon Faiz
Director
Transactions
- Purchase
Common Stock
2024-06-04$17.44/sh+65,337$1,139,477→ 1,069,135 total(indirect: By Trust) - Purchase
Common Stock
2024-05-31$16.14/sh+70,193$1,132,915→ 876,268 total(indirect: By Trust) - Purchase
Common Stock
2024-06-03$17.90/sh+80,738$1,445,210→ 1,003,798 total(indirect: By Trust) - Purchase
Common Stock
2024-06-04$18.24/sh+23,726$432,762→ 1,092,861 total(indirect: By Trust) - Purchase
Common Stock
2024-06-03$16.61/sh+46,792$777,215→ 923,060 total(indirect: By Trust)
Footnotes (5)
- [F1]The shares were purchased in multiple transactions at prices ranging from $15.75 to $16.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F2]The shares were purchased in multiple transactions at prices ranging from $16.25 to $16.75, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F3]The shares were purchased in multiple transactions at prices ranging from $17.40 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F4]The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F5]The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.